Contextual immersion trading strategy idea. Assertio Therapeutics, Inc., a specialty pharmaceutical company, provides medicines in neurology, orphan, and specialty areas in the United States. The demand for shares of the company looks higher than the supply. This and other conditions can cause a rise in the share price in the next days. So I opened a long...
Collegium Pharmaceutical (NASDAQ:COLL) +8.3% after-hours on news it agrees to acquire the U.S. rights to the Nucynta franchise from Assertio Therapeutics (NASDAQ:ASRT) for $375M; ASRT +56.7%. Collegium calls the deal "financially transformative... We expect the acquisition to improve annual EBITDA and operating cash flows by more than $100M." The company says...
Assertio therapeutics is slated to get an FDA ruling on its new drug application for cosyntropin depot by October 19. If the FDA approves the drug, the stock could move up significantly. Assertio has an 8.9/10 Equity StarMine Summary Score and is rated extremely undervalued by S&P Capital IQ. Despite relatively good earnings last quarter, the stock price is down...
Wave 5 soon be finished...abc correction should bring this higher....and then new start...